Understanding GLP-1 medications

Eli Lilly runs a free tool at scan.lilly.com that lets you point your phone camera at the 2D barcode on a Mounjaro or Zepbound package. The system checks the serial number against Lilly's database. If it matches, your medicine is probably genuine. If it doesn't, you know not to use it.

It's a good tool. But the site says it plainly: "This site is intended for US residents ages 18 and older." The scanner checks serial numbers against medicines "manufactured by Lilly and obtained in the United States." Indian-market Mounjaro and Yurpeak (the version distributed by Cipla) are not in that database.

India's serialization gap

India's pharmaceutical serialization system is patchy at best. The government mandated QR codes on the top 300 drug formulations in August 2023, but compliance has been poor. The older Track-and-Trace system for drug exports was formally withdrawn in January 2025. There's no reliable, consumer-facing way for an Indian patient to check that their GLP-1 injection is what the label says it is.

What we're doing about it

That's the gap GLPCheck is trying to fill. You can submit photos of your medicine's packaging and our team will check the box design, batch numbers, expiry dates, pen labels, and other visual markers against known authentic products. It's not instant and it's not automated, but it's available to anyone in India, for free. If something looks wrong, we'll tell you before you inject it.

Lilly does have a helpline for India (1800 123 0021), but it's a phone call, not a scanner. For patients here who want to verify their GLP-1 medication quickly, options are still limited.

Sources: Eli Lilly Verification Scanner · Eli Lilly Counterfeit Safety Hub

In April 2026, Haryana drug control officers stopped a vehicle near DLF Phase-4 in Gurugram and found over 260 counterfeit Mounjaro injection pens inside. A raid on a residential flat in Sector 62 followed, bringing the total seizure to roughly Rs 70 lakh.

Two men were arrested at the scene: a medical representative and a cab driver working as a courier. Investigators traced the operation to a third person who allegedly ran the whole setup from a rented apartment.

How the fakes were made

The process was disturbingly simple. Raw peptide powder was ordered from Chinese vendors on Alibaba, mixed with water, and loaded into injection pens. Packaging was reproduced using a 3D printer. According to Reuters, the accused learned how to prepare the injections from Google searches and YouTube videos.

Drug control officers spotted the fakes through small but telling differences: wrong shades of blue and red on the boxes, typographical errors, and font mismatches compared to genuine Mounjaro. The pens had not been stored at proper temperatures, and needle sterility could not be confirmed.

Where they were sold

The counterfeit stock was sold through IndiaMART at about 27% below market price, with supply traced back to Bhagirath Palace, one of Asia's largest wholesale pharmaceutical markets in Delhi. Eli Lilly issued a nationwide alert and confirmed that none of the seized pens came from their authorized supply chain.

This wasn't even the full extent of the operation. The same group was simultaneously selling an unapproved tirzepatide injection under a made-up brand called "Toneup," marketed as a Japanese import. It had zero approval from the DCGI or any state drug authority.

In a separate case, Delhi Police filed an FIR against a Dubai-based Indian national accused of defrauding a US company of Rs 157 crore in a fake Ozempic deal. The buyer paid for 125,000 doses and received spurious drugs shipped from China.

Sources: Reuters · The Week · Business Standard · Deccan Chronicle

An ASPA-CRISIL survey released in March 2026 put a number on something most people already suspected: roughly 28% of medicines sold in India are counterfeit. Among 1,639 consumers surveyed across nine cities, 89% said they'd purchased a fake product at least once.

GLP-1 medications are now part of that market. When Novo Nordisk's semaglutide patent expired on March 20, 2026, over 40 Indian manufacturers launched 50-plus generic versions within days. Prices dropped from Rs 8,800-16,400 per month to as low as Rs 1,290. That price crash was good news for patients. It was also good news for counterfeiters.

A global problem, not just an Indian one

The WHO has detected falsified GLP-1 products in nearly 60 countries since 2022. The US FDA has seized counterfeit Ozempic from legitimate supply chains three separate times: December 2023, April 2025, and December 2025. In some of those cases, the fake pens contained relabeled insulin instead of semaglutide. Patients expecting an appetite suppressant were injected with a blood sugar-lowering drug instead, causing hypoglycemia, seizures, and in some cases, coma.

Why India is especially vulnerable

Injectable GLP-1 drugs require cold-chain storage, and 63% of medicines in India move through local retail outlets with limited cold storage. Add high demand, dozens of unfamiliar new brands hitting shelves overnight, and a fragmented distribution network, and the conditions for fakes to slip through are hard to ignore.

Testing infrastructure is another weak spot. India doesn't have widely enforced, validated methods for testing GLP-1 peptide compounds across its labs. Results vary between facilities, making quality checks unreliable.

The legitimate GLP-1 market in India is growing fast. Injectable GLP-1 agonist sales hit Rs 1,736 crore in April 2026, up 218% year-on-year. Where there's money, there are fakes. For patients buying these drugs, the question isn't whether counterfeits exist in the supply chain. It's whether the specific pen in your hand is one of them.

Sources: WHO · FDA · ForgeStop · The Lancet

Jitendra Chouksey, the founder of fitness platform FITTR, has been asking one question since 2025: did the companies selling generic GLP-1 drugs in India actually run proper clinical trials before getting approval?

His team reviewed publicly available documents for several Indian pharma companies that launched generic semaglutide. Two companies had no Clinical Trial Registration on record. One had started trials only in China, not in India. A fourth company completed trials but never published results.

The RTI rejection

Chouksey's team filed an RTI request with CDSCO, India's drug regulator, asking for the clinical trial data these companies submitted to win approval. CDSCO turned them down, citing Section 8(1)(d) (confidentiality) and Section 8(1)(e) (competitive position of the companies).

Chouksey's argument is straightforward: clinical trial data affects public health. It shouldn't be hidden behind commercial confidentiality. Trial data isn't a trade secret. It's evidence that a drug is safe.

From RTI to the courtroom

In 2025, Chouksey filed a Public Interest Litigation in the Delhi High Court challenging the approval process for GLP-1 drugs used off-label for weight loss. The court directed CDSCO to review the matter within three months.

When CDSCO didn't comply, a contempt of court petition was filed in March 2026. The Delhi High Court issued notice and directed the DCGI and Union of India to respond.

Why this matters for patients

Injectable GLP-1 agonist sales in India jumped 177% between February 2025 and February 2026, from Rs 571 crore to Rs 1,446 crore. Over 40 generic manufacturers entered the market when semaglutide's patent expired. The question Chouksey keeps raising is whether patients can trust what's inside those pens when the trial data behind the approvals isn't public.

CDSCO did issue an advisory in March 2026 warning manufacturers against promotional activities for GLP-1 drugs. Chouksey's take: the advisory came 10 months after his first complaint, and only after a contempt petition forced their hand. He's said he plans to take the case to the Supreme Court.

Sources: Bar and Bench · YourStory · Business Standard · Medical Dialogues

If you're weighing your options, the conversation almost always comes down to two medicines: semaglutide and tirzepatide. A handful of others exist, but these two have the deepest clinical evidence and the largest pool of real-world experience behind them right now.

Semaglutide

Sold under the brand names Ozempic and Wegovy, semaglutide acts on the GLP-1 receptor. It dials down appetite, slows how quickly your stomach empties, and helps regulate blood sugar. In the STEP trials, participants lost an average of roughly 15% of their body weight over 68 weeks.

Tirzepatide

Marketed as Mounjaro and Zepbound, tirzepatide layers GIP receptor activation on top of the GLP-1 mechanism. That dual action showed up in the SURMOUNT trials as an average body weight reduction of around 20–22%. Interestingly, the second pathway also seems to ease GI side effects for some people compared with GLP-1 alone.

Give it time — this is the part most people get wrong

Here's something worth setting expectations around early: many people don't see meaningful weight loss until they reach the top one or two doses. The lower doses you start on aren't really there to drive results — they exist to let your body acclimatize to the medication while it builds to a steady state. Climbing to those higher doses is deliberately slow, and it can realistically take three to four months to get there.

Almost every day, someone arrives two weeks or a month in, frustrated that nothing has happened, asking whether they should switch medications, quit, or jump to the next dose ahead of schedule. Far more often than not, the issue isn't the drug — it's that the expectation was set too high, too soon. Those first couple of low doses simply aren't therapeutic doses; they're titration steps, meant to give your body room to adjust before the medication reaches the level where it actually does its work.

Practical considerations

• Both need a prescription. Neither is something you start on your own.
• Brand versions are pricey if you're paying out of pocket without insurance.
• Compounded versions through licensed pharmacies are far more affordable and accessible. That said, the FDA has been actively revising its stance on compounded GLP-1s, so check the current status before going that route.

Side effects

For both medicines, the side effects are mostly gastrointestinal — nausea above all, and especially during the titration phase. Both can also cause muscle loss alongside fat loss, which is worth getting ahead of with adequate protein and resistance training.

A note: none of this is medical advice, and I'm not a doctor. This is just one person who read a lot and wanted to organize it in a way that might help. Always make decisions with a qualified physician.

GLP-1 receptor agonists are a class of medicines originally developed for type 2 diabetes that are now widely used for weight management. They mimic a natural gut hormone — glucagon-like peptide-1 — that your body releases after eating.

How they work

GLP-1 medications act on several systems at once:

• They slow stomach emptying, so you feel full for longer.
• They signal the brain to reduce appetite and food cravings.
• They improve insulin response, which helps regulate blood sugar.

The combined effect is that most people eat less without feeling deprived.

Common options in India

The medicines you'll hear about most include semaglutide (sold as Wegovy and Ozempic), tirzepatide (Mounjaro), and liraglutide (Saxenda). They differ in how often you take them, how they're delivered, and their typical results.

Always start under the guidance of a qualified physician. Dosing is gradual, and the right choice depends on your health history.

What to expect

Results build over weeks, not days. Side effects — most commonly nausea — tend to be strongest when increasing the dose and usually ease over time. Pairing the medicine with realistic lifestyle changes gives the best long-term outcome.

Most GLP-1 side effects are mild and fade as your body adjusts. Here's what the community has found helpful in the first few weeks.

Nausea

The most common complaint. To reduce it:

• Eat smaller portions, and stop when you first feel full.
• Avoid greasy, fried, or very rich foods.
• Stay hydrated and sip water through the day.

Fatigue

Some people feel tired as their calorie intake drops. Make sure you're getting enough protein and not under-eating. Gentle movement often helps more than rest.

When to call your doctor

Reach out to your physician if you experience:

1. Severe or persistent abdominal pain
2. Vomiting that prevents you from keeping fluids down
3. Signs of dehydration

These are uncommon, but worth taking seriously.